A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients.

导出 LinkOut

翻译打印收藏纠错

第一作者： N,Khalladi

第一单位： Centre François Baclesse, 3, avenue General Harris, 14076 Caen, France.

作者： N,Khalladi ^[1] ; C,Dejean ^[2] ; M,Bosset ^[3] ; Y,Pointreau ^[4] ; R,Kinj ^[2] ; S,Racadot ^[5] ; J,Castelli ^[6] ; F,Huguet ^[7] ; S,Renard ^[8] ; S,Guihard ^[9] ; Y,Tao ^[10] ; J M,Rouvier ^[11] ; A,Johnson ^[1] ; J,Bourhis ^[12] ; S,Xu Shan ^[12] ; J,Thariat ^[13]

作者单位： Centre François Baclesse, 3, avenue General Harris, 14076 Caen, France. ^[1] Centre Antoine Lacassagne, Nice, France. ^[2] Centre Marie Curie, Valence, France. ^[3] Centre Jean Bernard, Mans-Tours, France. ^[4] Center Léon Bérard, Lyon, France. ^[5] Center Eugene Marquis, Rennes, France. ^[6] Centre hospitalier et universitaire Tenon, Paris, France. ^[7] Institut de Cancérologie de Lorraine, Nancy, France. ^[8] Institut de Cancérologie Strasbourg Europe, Strasbourg, France. ^[9] Institut Gustave Roussy, Villejuif, France. ^[10] Centre hospitalier régional et universitaire, Besançon-Montbéliard, France. ^[11] Centre hospitalier universitaire vaudois, Lausanne, Switzerland. ^[12] Centre François Baclesse, 3, avenue General Harris, 14076 Caen, France; Corpuscular Physics Laboratory-Normandy University, Caen, France. Electronic address: jthariat@gmail.com. ^[13]

关键词 Assurance qualité Benchmark case Cancer Clinical trial Deviation Déviation Essai clinique Head and neck ORL Quality assurance Radiothérapie stéréotaxique Stereotactic radiotherapy